Investor Toolbox
Listen to Call
Recording not yet available.
Read Transcript
Transcript not yet available.
View Infographic
Infographic not yet available.
MRK Coverage
Event
Merck & Co., Inc. (MRK) KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
Feb 11, 2026
Event
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call
Feb 10, 2026
Transcript
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Feb 4, 2026
Transcript
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Jan 22, 2026
Transcript
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Jan 22, 2026
News
Key highlights from Merck’s (MRK) Q3 2025 earnings results
Oct 30, 2025
News
Infographic: How Merck (MRK) performed in Q3 2024
Oct 31, 2024
News
Merck (MRK) swings to profit in Q2 on higher revenues; earnings beat
Jul 30, 2024